Vasomotor (perennial chronic) conjunctivitis

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 355-360

  Bielory, Leonard ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b DOC   (United States)

Author keywords

Nonallergic noninfectious conjunctivitis; Perennial chronic conjunctivitis; Vasomotor conjunctivitis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AZELASTINE; CORTICOSTEROID; DOXYCYCLINE; EPINASTINE; IMMUNOGLOBULIN E; KETOTIFEN; OLOPATADINE;

ALLERGIC CONJUNCTIVITIS; CHRONIC DISEASE; COMORBIDITY; CONJUNCTIVA; HUMAN; IMMUNOTHERAPY; PARAMETER; PATHOPHYSIOLOGY; PERENNIAL ALLERGIC CONJUNCTIVITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VASOMOTOR CONJUNCTIVITIS; VASOMOTOR DISORDER;

ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS; HUMANS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; VASOMOTOR SYSTEM;

EID: 33748562503     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244796.48981.24     Document Type: Review

References (52)

1. Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol 2000; 106:1019-1032.
2. Bielory L. Allergic and immunologic disorders of the eye. Part I: Immunology of the eye. J Allergy Clin Immunol 2000; 106:805-816.
3. Bielory L. Allergic diseases of the eye. Med Clin North Am 2006; 90:129-148. An interesting article that heightens our awareness of the IgE and non-IgE-mediated process that may have similar presentations. It provides a perspective on evidence-based recommendations on allergy testing, but not necessarily the diagnosis of the non-IgE-mediated disorders.
4. Bielory L. Ocular allergy and dry eye syndrome. Curr Opin Allergy Clin Immunol 2004; 4:421-424.
5. Groneberg , Bielory L, Fischer A, et al. Animal models of allergic and inflammatory conjunctivitis. Allergy 2003; 58:1101-1113.
6. Bielory L, Dinowitz M, Rescigno R. Ocular allergic diseases: differential diagnosis examination techniques and testing. J Toxicol 2002; 21:329-351.
7. Bielory L, Bonini S. Allergic eye disorders. Clin Allergy Immunol 2002; 16:311-323.
8. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62:1611-1634.
9. Bielory L, Goodman PE, Fisher EM. Allergic ocular disease: a review of pathophysiology and clinical presentations. Clin Rev Allergy Immunol 2001; 20:183-200.
10. Committee IS. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351:1225-1232.
11. Bodtger U, Poulsen LK, Malling HJ. Asymptomatic skin sensitization to birch predicts later development of birch pollen allergy in adults: a 3-year follow-up study. J Allergy Clin Immunol 2003; 111:149-154.
12. Sivko MT. Vasomotor conjunctivitis. Oftalmol Zh 1971; 26:306-307.
13. Rosen Z, Davis E. The small blood vessels of the conjunctiva and nailfold in vasomotor rhinopathy. Trans Indiana Acad Ophthalmol Otolaryngol 1964; 47:34-39.
14. Pastorello EA, Codecasa LR, Pravettoni V, et al. Clinical reliability of diagnostic tests in allergic rhinoconjunctivitis. Boll Ist Sieroter Milan 1988; 67:377-385.
15. Enberg RN. Perennial nonallergic rhinitis: a retrospective review. Ann Allergy 1989; 63 (6 Pt 1):513-516.
16. Leynaert B, Bousquet F , Neukirch C, et al. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104 (2 Pt 1):301-304.
17. Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65:122-126.
18. Davies RJ, Rusznak C, Devalia JL. Why is allergy increasing? Environmental factors. Clin Exp Allergy 1998; 28 (Suppl 6):8-14.
19. Rusznak C, Devalia JL, Davies RJ. The impact of pollution on allergic disease. Allergy 1994; 49 (18 Suppl):21-27.
20. Viswanathan S, Eria L, Diunugala N, et al. An analysis of effects of San Diego wildfire on ambient air quality. J Air Waste Manag Assoc 2006; 56:56-67. Demonstrated that the increased particulate matter concentration above the federal standard resulted in a significant increase in eye irritation in addition to increased hospital emergency room visits for asthma and other respiratory problems. The ocular symptoms were similar to those in patients with allergic rhinoconjunctivitis.
21. Doughty MJ, Blades KA, Ibrahim N. Assessment of the number of eye symptoms and the impact of some confounding variables for office staff in nonair-conditioned buildings. Ophthalmic Physiol Opt 2002; 22:143-155.
22. Backman H, Haghighat F. Indoor-air quality and ocular discomfort. J Am Optom Assoc 1999; 70:309-316.
23. Muzi G, dell'Omo M, Abbritti G, et al. Objective assessment of ocular and respiratory alterations in employees in a sick building. Am J Ind Med 1998; 34:79-88.
24. Lindgren T, Andersson K, Dammstrom BG, et al. Ocular, nasal, dermal and general symptoms among commercial airline crews. Int Arch Occup Environ Health 2002; 75:475-483.
25. Ng TP, Tan WC. Epidemiology of chronic (perennial) rhinitis in Singapore: prevalence estimates, demographic variation and clinical allergic presentation. Ann Acad Med Singapore 1994; 23:83-88.
26. Eigenmann PA. Diagnosis of allergy syndromes: do symptoms always mean allergy? Allergy 2005; 60 (Suppl 79):6-9. An interesting article that heightens the awareness of the IgE and non-IgE-mediated process that may have similar presentations. Provides a perspective on evidence-based recommendations on allergy testing, but not necessarily the diagnosis of the non-IgE-mediated disorders.
27. Baudouin C, Bourcier T, Brignole F, et al. Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2000; 238:900-904.
28. Bourcier T, Moldovan M, Goldschild M, et al. Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis. J Fr Opthalmol 1998; 21:209-213.
29. Bonini S, Bonini S. Mechanisms in adverse reactions to food: the eye. Allergy 1995; 50 (20 Suppl):68-73.
30. Bonini S. IgE and non-IgE mechanisms in ocular allergy. Ann Allergy 1993; 71:296-299.
31. Feniksova LV, Rybalkin SV, Pekli FF. Study of the changes in microcirculatory bed in children with vasomotor rhinitis based on biomicroscopy of conjunctival blood vessels. Vestn Otorinolaringol 1990; (4):42-44.
32. Szentivanyi M, Pek L. Characteristic changes of vascular adrenergic reactions in diabetes mellitus. Nat New Biol 1973; 243:276-277.
33. Starr PA. Oculocutaneous aspects of rosacea. Proc R Soc Med 1969; 62:9-11.
34. Piovella C, Fratti L, Fontana S. Modification of the terminal circulation in Raynaud's disease and acrocyanosis. Bibl Anat 1965; 7:552-558.
35. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000;160:1101-1108.
36. Tosca M, Ciprandi G, Passalacqua G, et al. Cetirizine reduces conjunctival nonspecific hyperreactivity in children with mite allergy. J Investig Allergol Clin Immunol 1998; 8:23-26.
37. Ciprandi G, Catrullo A, Tosca M, et al. Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. J Investig Allergol Clin Immunol 1999; 9:35-38.
38. Bonini S. Mechanisms in adverse reactions to food: rhe eye. Allergy 1995; 50 (20 Suppl):68-73.
39. Blondin C, Cholley B, Haeffner-Cavaillon N, et al. In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter. J Fr Ophtalmol 2003; 26:328-336.
40. Pflugfelder SC, Solomon A, Dursun D, Li DQ. Dry eye and delayed tear clearance: 'a call to arms'. Adv Exp Med Biol 2002; 506 (Pt B):739-743.
41. Sanico AM, Philip G, Proud D, et al. Comparison of nasal mucosal responsiveness to neuronal stimulation in non-allergic and allergic rhinitis: effects of capsaicin nasal challenge. Clin Exp Allergy 1998; 28:92-100.
42. Yamaji M, Takada M, Fujiwara R, et al. Role of substance P in experimental allergic conjunctivitis in guinea pigs. Methods Find Exp Clin Pharmacol 1997; 19:637-643.
43. Saria A, Hua X, Skofitsch G, Lundberg JM. Inhibition of compound 48/80-induced vascular protein leakage by pretreatment with capsaicin and a substance P antagonist. Naunyn Schmiedebergs Arch Pharmacol 1984; 328:9-15.
44. Yoshida A, Fujihara T, Nakata K. Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Exp Eye Res 1999; 68:541-546.
45. Ciprandi G, Buscaglia S, Pesce G, et al. Effects of conjunctival hyperosmolar challenge in allergic subjects and normal controls. Int Arch Allergy Immunol 1994; 104:92-96.
46. Bonini S, Bonini S, Schiavone M, et al. Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis. J Allergy Clin Immunol 1992; 89 (1 Pt 1):103-107.
47. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001; 22:185-189.
48. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45:4302-4311.
49. Tamura T, Matsubara M, Hasegawa K, et al. Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy 2005; 35:97-103.
50. Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002; 88:501-506.
51. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
52. Konno S, Asano K, Okamoto K, Adachi M. Inhibition of cytokine production from human peripheral blood leukocytes by antiallergic agents in vitro. Eur J Pharmacol 1994; 264:265-268.